Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Bile Duct Cancer...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Solid Tumor: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Solid Tumor. According...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Esophageal Squamous Cell...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Metastatic Biliary Tract Cancer: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Metastatic Biliary Tract...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Extrahepatic Bile Duct Cancer: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Extrahepatic Bile Duct...
TQB-2223 by Chia Tai Tianqing Pharmaceutical Group for Gallbladder Cancer: Likelihood of Approval
TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Gallbladder Cancer. According...